HK1040620A1 - 治疗流感的肽基疫苗 - Google Patents

治疗流感的肽基疫苗 Download PDF

Info

Publication number
HK1040620A1
HK1040620A1 HK02102105.6A HK02102105A HK1040620A1 HK 1040620 A1 HK1040620 A1 HK 1040620A1 HK 02102105 A HK02102105 A HK 02102105A HK 1040620 A1 HK1040620 A1 HK 1040620A1
Authority
HK
Hong Kong
Prior art keywords
epitopes
influenza
epitope
influenza virus
hla molecules
Prior art date
Application number
HK02102105.6A
Other languages
English (en)
Chinese (zh)
Inventor
Arnon Ruth
Ben-Yedidia Tamar
Levi Raphael
Original Assignee
耶达研究及发展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 耶达研究及发展有限公司 filed Critical 耶达研究及发展有限公司
Publication of HK1040620A1 publication Critical patent/HK1040620A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK02102105.6A 1998-11-30 1999-11-28 治疗流感的肽基疫苗 HK1040620A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12733198 1998-11-30
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
PCT/IL1999/000640 WO2000032228A2 (en) 1998-11-30 1999-11-28 Peptide-based vaccine for influenza

Publications (1)

Publication Number Publication Date
HK1040620A1 true HK1040620A1 (zh) 2002-06-21

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102105.6A HK1040620A1 (zh) 1998-11-30 1999-11-28 治疗流感的肽基疫苗

Country Status (15)

Country Link
US (3) US6740325B1 (https=)
EP (2) EP2204187B1 (https=)
JP (1) JP2002531415A (https=)
KR (1) KR100703571B1 (https=)
AT (1) ATE556719T1 (https=)
AU (1) AU766883B2 (https=)
BR (1) BR9915811A (https=)
CA (1) CA2352454C (https=)
DK (1) DK2204187T3 (https=)
ES (1) ES2389611T3 (https=)
HK (1) HK1040620A1 (https=)
IL (3) IL127331A0 (https=)
NZ (1) NZ511918A (https=)
PT (1) PT2204187E (https=)
WO (1) WO2000032228A2 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
WO2002026252A1 (en) * 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
DK1692265T3 (da) 2003-11-04 2011-11-21 Univ Tulane Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US20060177468A1 (en) * 2005-01-05 2006-08-10 Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine Delivery vehicles, bioactive substances and viral vaccines
TW200640485A (en) 2005-01-19 2006-12-01 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
CA2610667A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
EP1948227A4 (en) * 2005-10-26 2010-03-31 Protelix Inc COMBINATORY ANTIGEN VACCINE AGAINST FLU
CA2628837C (en) * 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
WO2007066334A1 (en) * 2005-12-06 2007-06-14 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
EP3753574A1 (en) * 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
WO2008002663A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
EP2173376B1 (en) 2007-08-02 2015-03-25 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
WO2009131995A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
CN102046198A (zh) * 2008-04-25 2011-05-04 系统生物学研究所 鞭毛蛋白多肽疫苗
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US9492525B2 (en) 2011-07-06 2016-11-15 Nanobio Corporation Human respiratory syncytial virus vaccine
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
JP6497691B2 (ja) 2013-02-05 2019-04-10 日東電工株式会社 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
US20140220079A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for mucosal administration
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
RU2014102941A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
IN2014CH00395A (https=) 2013-02-05 2015-04-03 Nitto Denko Corp
EP3662927A3 (en) 2013-02-05 2020-10-21 Nitto Denko Corporation Vaccine composition
KR102050931B1 (ko) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
EP2762154A3 (en) 2013-02-05 2015-01-21 Nitto Denko Corporation Vaccine composition for transdermal administration
EP2762158A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
JP6577795B2 (ja) 2014-09-03 2019-09-18 日東電工株式会社 ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
CN106687127A (zh) 2014-09-03 2017-05-17 日东电工株式会社 含有双膦酸盐剂的体液免疫用疫苗药物组合物
EP3332809A4 (en) 2015-08-06 2019-04-10 Nitto Denko Corporation COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND PHARMACEUTICAL VACCINE COMPOSITION
AU2017386682A1 (en) 2016-12-28 2019-07-25 Invvax, Inc. Influenza vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
AU1406600A (en) 2000-06-19
KR20010089512A (ko) 2001-10-06
EP2204187A1 (en) 2010-07-07
ES2389611T3 (es) 2012-10-29
BR9915811A (pt) 2001-08-21
IL143367A0 (en) 2002-04-21
HK1145448A1 (en) 2011-04-21
US7514086B2 (en) 2009-04-07
EP1135159A2 (en) 2001-09-26
US6740325B1 (en) 2004-05-25
IL143367A (en) 2006-09-05
CA2352454A1 (en) 2000-06-08
NZ511918A (en) 2003-08-29
US20050002954A1 (en) 2005-01-06
EP2204187B1 (en) 2012-05-09
KR100703571B1 (ko) 2007-04-05
ATE556719T1 (de) 2012-05-15
WO2000032228A2 (en) 2000-06-08
IL127331A0 (en) 1999-09-22
DK2204187T3 (da) 2012-08-20
PT2204187E (pt) 2012-08-10
CA2352454C (en) 2013-02-05
US20070122424A1 (en) 2007-05-31
AU766883B2 (en) 2003-10-23
JP2002531415A (ja) 2002-09-24
WO2000032228A3 (en) 2000-10-05
US7192595B2 (en) 2007-03-20

Similar Documents

Publication Publication Date Title
WO2000032228A3 (en) Peptide-based vaccine for influenza
JP2002531415A5 (https=)
Liu et al. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
UY27552A1 (es) 17a- alquil- 17b- oxi-estratrienos y productos intermediarios para su preparacinn, uso de los 17a-alquil-17b-oxi-estratrienos para obtener medicamentos y preparados farmacéuticos.
EE200000378A (et) Adamantaani derivaadid
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
WO2003076603A3 (en) Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
EP0804158A4 (en) PREPARATIONS AND METHOD FOR TRIGGERING CTL IMMUNITY
WO2008068631A3 (en) Vaccines including antigen from four strains of influenza virus
PT1036058E (pt) Deribvados de adamantano
BR0009580A (pt) Composição, processos para preparar vìrus da influenza, para preparar um veìculo de liberação de genes, para preparar vìrus da influenza defeituosos de replicação infecciosa, para imunizar um paciente contra um patógeno, para preparar vìrus infeccioso, e para preparar vìrus, vìrus, célula, vetor, célula hospedeira, e, uso do vìrus
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
MY125978A (en) Admantane derivatives
ES2121830T3 (es) Procedimiento para la preparacion a escala industrial de un concentrado de factor de willebrand humano normalizado de pureza muy elevada apropiado para uso terapeutico.
IL150602A0 (en) Proteosome influenza vaccine
AU4622693A (en) Potentiation of immunogenic response
DE69620761D1 (de) Pharmazeutisches praeparat auf der basis eines diclofenac-salzes und der verbindung thiocolchicosid
WO1994026903A3 (en) Human influenza virus peptides binding hla-i molecule
CA2521038A1 (en) Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
DE3370477D1 (en) Acetylcysteine salts, their preparation and use
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
PT989994E (pt) Derivados de estreptograminas, a sua preparacao e as composicoes que os contem
NO20005258L (no) Fremgangsmåte for konvertering av ekinocandinklassen av peptider til deres C4-homotyrosinmonodeoksyanaloger